Clinical Trial Update: Study of ALLN-177 in Patients Aged 12 Years or Older With Enteric or Primary Hyperoxaluria and Hyperoxalemia [Phase 2]

View source ↗

Summary

Phase 2 trial update for ALLN-177 in patients aged 12 and older with enteric or primary hyperoxaluria and hyperoxalemia has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Enteric Hyperoxaluria
• Hyperoxalemia
• Hyperoxaluria

Drugs mentioned

• ALLN-177

Snippet

Sponsor: Allena Pharmaceuticals | Conditions: Enteric Hyperoxaluria, Primary Hyperoxaluria | Phase 2 | Status: COMPLETED